
A multicenter randomized trial of 276 patients with sepsis found that precision immunotherapy targeting immune dysfunction improved organ failure scores by day 9 compared with placebo. Although mortality differences were not statistically significant, the results suggest that biomarker-guided treatment strategies could help personalize sepsis care and improve clinical outcomes.























